The investigators explained that GLP-1 receptor agonists appear to be able to help resolve MASH without worsening fibrosis. Those findings have been confirmed in mouse models and in multiple studies ...
A new approach to weight loss research is challenging one of the biggest assumptions behind popular weight loss drugs: Are ...
Peptide-based substances are largely unproven and risky, experts say, but they’re gaining popularity among influencers and ...
In animal studies, an experimental drug targeting both GIP and glucagon led to equal or greater weight loss compared to ...
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin analogues that promote glucose-mediated insulin release and are used to treat type 2 diabetes mellitus and obesity. GLP-1 receptor ...
Yet another weight loss drug is causing a stir online. But health authorities and experts say it may bring more risks than ...
Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. The Food and ...
In the latest tranche of published warning letters, the US Food and Drug Administration (FDA) has continued to go after ...
The Food and Drug Administration (FDA) is taking the first steps toward potentially easing access to certain peptide ...
One of these is retatrutide, a drug that’s being described as the next big thing in weight loss. Some say it may be even more ...
Under the new priority voucher program (CNPV), the FDA has approved a new oral GLP-1 drug, Foundayo, offering an alternative ...
A black market is flourishing for new injectable drugs that have yet to be properly tested for safety and effectiveness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results